Anavex Life Sciences Corp (AVXL)

[Talon38]

Plmer. No one knows for sure whether the testing covered by the MTA is complete. It is more than probable that Biogen requested to test 2-73 occasioned by the problems with their prime remyelination drug, Opicinumab, and after they were aware of the Wayne State positive report on 2-73's remyelination properties. Follow on negotiations may or have led to additional testing possibly in combo with Opicinumab. Out licensing of 2-73 to Biogen would put it in their trials pipeline.


As I have said before, no bio has more to gain or lose from the success of 2-73 than Biogen.